Back to Screener

Revelation Biosciences, Inc. Warrant (REVBW)

Price$0.01

Favorite Metrics

Price vs S&P 500 (26W)-54.68%
Price vs S&P 500 (4W)-11.60%

All Metrics

Price vs S&P 500 (YTD)12.93%
10-Day Avg Trading Volume0.01M
3-Month Avg Trading Volume0.04M
52-Week High$0.02
26-Week Price Return-45.93%
13-Week Price Return-18.42%
3-Month Return Std Dev122.91%
Year-to-Date Return16.25%
5-Day Price Return6.90%
Month-to-Date Return2.20%
Price vs S&P 500 (13W)-21.29%
Beta3.02x
52-Week Low$0.01

Industry Peers — Pharmaceuticals(309)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
REVBWRevelation Biosciences, Inc. Warrant
$0.01
LLYEli Lilly & Co.
13.45x44.70%83.04%27.59%$919.90
JNJJohnson & Johnson
5.82x7.87%67.95%14.90%$230.69
ABBVABBVIE INC.
5.97x8.57%71.62%-2.88%$203.71
MRKMerck & Co., Inc.
4.51x1.31%78.55%21.23%$117.10
AZNAstraZeneca PLC
5.39x8.63%81.31%21.88%$200.69
NVSNovartis AG
4.87x8.91%75.82%15.26%$150.99
NVONovo-Nordisk A/S
3.74x6.43%80.98%20.66%$40.46
ABTAbbott Laboratories
3.71x6.59%56.50%8.20%$96.00
PFEPfizer Inc.
2.50x-1.64%75.81%-3.51%$27.52
BMYBristol-Myers Squibb Co.
2.52x-0.22%72.63%$59.13

About

Revelation Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of immunotherapy products based on Gemini, its proprietary TLR4 agonist formulation designed to harness the body's innate immune response to treat inflammatory diseases. The company is advancing three Gemini-based candidates targeting high-value indications: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.